New treatment options for panic disorder: Clinical trials from 2000 to 2010

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 9, 2011, Pages 1419-1428

  Freire, Rafael C ^a   Hallak, Jaime E ^b   Crippa, Joséé A ^b   Nardi, Antonio E ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antidepressant; benzodiazepine; review; treatment

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; INOSITOL; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; OLANZAPINE; PAROXETINE; PINDOLOL; PLACEBO; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANOREXIA; ASTHENIA; ATAXIA; CONSTIPATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GABAERGIC SYSTEM; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MEDICAL LITERATURE; MEDLINE; MEMORY DISORDER; META ANALYSIS; NAUSEA; NORADRENERGIC SYSTEM; OPEN STUDY; PANIC; RESTLESSNESS; REVIEW; RISK ASSESSMENT; SEDATION; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; SYSTEMATIC REVIEW; TREMOR; UNSPECIFIED SIDE EFFECT; VERTIGO; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; HUMANS; PANIC DISORDER; SEROTONIN;

EID: 79956145690     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.562200     Document Type: Review

References (63)

1. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. 2nd edition. American Psychiatric Publishing, Inc., Washington, DC; 2009
2. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th edition (DSM-IV). American Psychiatric Press, Washington, DC; 1994
3. Roy-Byrne PP, Stang P, Wittchen HU, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry 2000;176:229-35 (Pubitemid 30179841)
4. Lepine JP. Epidemiology, burden, and disability in depression and anxiety. J Clin Psychiatry 2001;62(Suppl 13):4-10
5. Lepine JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry 2002;63(Suppl 14):4-8
6. Bystritsky A, Kerwin L, Niv N, et al. Clinical and subthreshold panic disorder. Depress Anxiety 2010;27:381-9
7. Altamura AC, Santini A, Salvadori D, Mundo E. Duration of untreated illness in panic disorder: a poor outcome risk factor? Neuropsychiatr Dis Treat 2005;1:345-7
8. Slaap BR, den Boer JA. The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress Anxiety 2001;14:112-22 (Pubitemid 32937485)
9. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005;88:27-45 (Pubitemid 41160411)
10. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505 (Pubitemid 30191187)
11. Nardi AE, Freire RC, Zin WA. Panic disorder and control of breathing. Respir Physiol Neurobiol 2009;167:133-43
12. Cecchi M, Khoshbouei H, Javors M, Morilak DA. Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience 2002;112:13-21 (Pubitemid 34603494)
13. Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am 2009;32:549-75
14. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004;7:193-218 (Pubitemid 38823288)
15. Kjernisted K, McIntosh D. Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag 2007;3:59-69 (Pubitemid 46671824)
16. Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002;106:163-7
17. Nardi AE, Lopes FL, Valenca AM, et al. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res 2010;175:260-5
18. Bailey JE, Papadopoulos A, Seddon K, Nutt DJ. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. J Psychopharmacol 2009;23:117-22
19. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-71 (Pubitemid 30463763)
20. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995;15:819-44 (Pubitemid 26011957)
21. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007;27:263-72 (Pubitemid 46763308)
22. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248-312
23. Royal Australia and New Zealand College of Psychiatrists. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust NZ J Psychiatry 2003;37:641-56
24. Doble A, Martin I. Insights into the mechanisms of benzodiazepine dependence. Eur Neuropsychopharmacol 2000;10:169
25. Nardi AE, Valenca AM, Nascimento I, et al. A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam. Psychiatry Res 2005;137:61-70 (Pubitemid 41550129)
26. Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001;158:1989-92 (Pubitemid 33104103)
27. American Psychiatric Association. APA practice guidelines for the treatment of psychiatric disorders. American Psychiatric Press, Washington, DC; 2006
28. Mochcovitch MD, Nardi AE. Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies. Expert Rev Neurother 2010;10:1285-93
29. Bertani A, Caldirola D, Bussi R, et al. The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. J Clin Psychopharmacol 2001;21:262-7 (Pubitemid 32452930)
30. Bertani A, Bellodi L, Bussi R, et al. The effect of one-week treatment with venlafaxine on 35% CO2 hyperreactivity in patients with panic disorder: an open study. J Clin Psychopharmacol 2003;23:106-8 (Pubitemid 36164436)
31. Sarchiapone M, Amore M, De RS, et al. Mirtazapine in the treatment of panicdisorder: an open-label trial. Int Clin Psychopharmacol 2003;18:35-8 (Pubitemid 36127059)
32. Boshuisen ML, Slaap BR, Vester-Blokland ED, den Boer JA. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol 2001;16:363-8 (Pubitemid 33030053)
33. Carli V, Sarchiapone M, Camardese G, et al. Mirtazapine in the treatment of panic disorder. Arch Gen Psychiatry 2002;59:661-2
34. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 2002;17:329-33 (Pubitemid 35189814)
35. Papp LA, Coplan JD, Martinez JM, et al. Efficacy of open-label nefazodone treatment in patients with panic disorder. J Clin Psychopharmacol 2000;20:544-6
36. Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001;104:289-98 (Pubitemid 32906975)
37. Simon NM, Kaufman RE, Hoge EA, et al. Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther 2009;15:19-23
38. Cia AH, Brizuela JA, Cascardo E, Varela MF. Clonazepam and milnacipran in the treatment of patients with panic disorder and comorbid major depression. Prim Care Community Psychiatr 2006;11:51-6 (Pubitemid 44803631)
39. Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001;103:1-14 (Pubitemid 32709996)
40. Ferguson JM, Khan A, Mangano R, et al. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 2007;68:58-68 (Pubitemid 46220125)
41. Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007;24:1-14 (Pubitemid 46278675)
42. Pollack M, Mangano R, Entsuah R, et al. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 2007;194:233-42 (Pubitemid 47457944)
43. Sheehan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005;66:34-40
44. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003;64:1322-7 (Pubitemid 37490237)
45. Valenca AM, Nardi AE, Nascimento I, et al. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr 2000;58:1025-9
46. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002;63:31-7 (Pubitemid 34113484)
47. Zwanzger P, Eser D, Nothdurfter C, et al. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry 2009;42:266-9
48. Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 2004;65:405-13
49. Lepola U, Arato M, Zhu Y, Austin C. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 2003;64:654-62 (Pubitemid 36750142)
50. Mavissakalian MR. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry 2003;15:171-80 (Pubitemid 38176336)
51. Cavaljuga S, Licanin I, Kapic E, Potkonjak D. Clomipramine and fluoxetine effects in the treatment of panic disorder. Bosn J Basic Med Sci 2003;3:27-31
52. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001;34:1303-7 (Pubitemid 33014498)
53. Perna G, Bertani A, Caldirola D, et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001;34:85-90 (Pubitemid 32531127)
54. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001;21:335-9 (Pubitemid 32452940)
55. Schruers K, Griez E. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. J Psychopharmacol 2004;18:553-8 (Pubitemid 39665123)
56. Bertani A, Perna G, Migliarese G, et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2004;37:206-10 (Pubitemid 39286922)
57. Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:556-9
58. Pollack MH, Simon NM, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003;17:276-82 (Pubitemid 37150836)
59. Hoge EA, Worthington JJ III, Kaufman RE, et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr 2008;13:522-7 (Pubitemid 351960777)
60. Sepede G, De BD, Gambi F, et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol 2006;26:45-9 (Pubitemid 43167090)
61. McIntosh A, Cohen A, Turnbull N, et al. Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder. University of Sheffield/London: National Collaborating Centre for Primary Care, Sheffield; 2004
62. Yeragani VK, Pohl R, Jampala VC, et al. Effects of nortriptyline and paroxetine on QT variability in patients with panic disorder. Depress Anxiety 2000;11:126-30 (Pubitemid 30347189)
63. Mavissakalian M, Perel J, Guo S. Specific side effects of long-term imipramine management of panic disorder. J Clin Psychopharmacol 2002;22:155-61 (Pubitemid 34289390)